Premium
Retracted : Analgesic effects of microRNA‐129‐5p against bone cancer pain through the EphB1/EphrinB2 signaling pathway in mice
Author(s) -
Yu ShaoNan,
Liu GuiFeng,
Li LongYun,
Zhao GuoQing,
Liu Lin,
Li XueFeng
Publication year - 2019
Publication title -
journal of cellular biochemistry
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.028
H-Index - 165
eISSN - 1097-4644
pISSN - 0730-2312
DOI - 10.1002/jcb.26605
Subject(s) - messenger rna , microrna , chemistry , western blot , signal transduction , analgesic , downregulation and upregulation , pharmacology , gene , microbiology and biotechnology , biochemistry , biology
The study aims to investigate the analgesic effects of microRNA‐129‐5p (miR‐129‐5p) on bone cancer pain (BCP) by targeting Eph receptor B1 (EphB1) through the EphB1/EphrinB2 signaling pathway. BCP mice models were established, and C3H/HeJ female mice were classified into the normal, blank, negative control (NC), miR‐129‐5p mimics, miR‐129‐5p inhibitors, EphB1 knockout (KO), and miR‐129‐5p inhibitors + EphB1 KO groups. Quantitative reverse transcription polymerase chain reaction and Western blot analysis were used to evaluate the miR‐129‐5p expression, and messenger RNA (mRNA) and protein expressions of EphB1, p‐EphB1, EphrinB2, and p‐EphrinB2. EphB1 and EphrinB2 were highly activated in the tibias of BCP mice 7 days after the operation. EphB1 is a target gene of miR‐129‐5p. The mechanical withdrawal threshold increased in the miR‐129‐5p mimics, EphB1 KO and miR‐129‐5p inhibitors + EphB1 KO groups, but decreased in the miR‐129‐5p inhibitors group. Compared with the blank and the NC groups, the expression of miR‐129‐5p was significantly increased in the miR‐129‐5p mimics group, and the mRNA and protein expressions of EphrinB2, p‐EphrinB2, EphB1, and p‐EphB1 were significantly decreased, while in the miR‐129‐5p inhibitors group, the results were opposite (all P < 0.05); the mRNA and protein expressions of EphrinB2, p‐EphrinB2, EphB1, and p‐EphB1 were significantly decreased in the EphB1 KO group (all P < 0.05); the expression of miR‐129‐5p was significantly decreased in the miR‐129‐5p inhibitors + EphB1 KO group ( P < 0.05), while the mRNA and protein expressions of EphrinB2 and p‐EphrinB2 were not significantly different ( P > 0.05). The results indicated that upregulated miR‐129‐5p alleviate BCP via downregulation of the EphB1/EphrinB2 signaling pathway.